Single Doses GSK159797 On Patient Safety And Lung Function In Patients With Mild To Moderate Asthma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-09-30

Study Completion Date

2004-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study was designed to test safety aspects and effects on lung function of a new dry powder version of GSK159797 for asthmatic subjects to inhale. This will allow comparison with previous studies which have only used inhalation of the drug as a vapour.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Evaluate GSK2190915 in Subjects With Mild Asthma

NCT00812773

Asthma

COMPLETED PHASE2

Study To Evaluate GSK256066 In Subjects With Mild Bronchial Asthma

NCT00380354

Asthma Mild Asthma

COMPLETED PHASE2

Study to Investigate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Single & Repeat Doses of GSK2269557

NCT01462617

Asthma

COMPLETED PHASE1

Study in Mild Asthmatic Patients

NCT00748306

Asthma

COMPLETED PHASE2

A Study to Investigate the Efficacy, Safety, and Tolerability of Repeat Doses of Inhaled GSK2269557 in Adults With Persistent, Uncontrolled Asthma

NCT02567708

Pulmonary Disease, Chronic Obstructive

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Disease, Chronic Obstructive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GSK159797

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects with mild to moderate stable asthma but no other lung problems.
* Male subjects or females who are not able to get pregnant (e.g. post-menopausal or surgically sterile).
* Non-smokers.
* Subjects that show a measurable improvement in the function of their lungs after a single dose of salbutamol.

Exclusion Criteria

* Any significant illness.
* Subjects with heart problems.
* Subjects who have had a cold or chest infection 2-4 weeks prior to the study.
* Subjects who take medication for their asthma, or other conditions, not compatible with the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No